C. Halluard

Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine

J. Limacher, P. Erbs, J. Delord, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice

S. Braun, A. Pavirani, F. Perraud, 2000, Gene Therapy.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

E. Felip, J. Adam, A. Szczesna, 2016, The Lancet. Oncology.

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

F. Zoulim, C. Coffin, A. Lohse, 2019, Human vaccines & immunotherapeutics.

Molecular Markers PCNA, Ki-67 and Cathepsin D in Patients with Colorectal Cancer and their Relationship with Lymph Node Involvement

J. Limacher, P. Erbs, J. Delord, 2010 .

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

R. Ramlau, M. Krzakowski, E. Tartour, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vectorized Gene Therapy of Liver Tumors: Proof of Concept of TG4023 (MVA-FCU1) in Combination with Flucytosine.

J. Limacher, P. Erbs, J. Delord, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.